Speaking to Hikma executive chairman and CEO Said Darwazah immediately after the company reported flat half-year sales and revised down its generics forecasts for the second time this year, the chief executive made clear that the company has a strategy in place to return the company to growth across all three of its business units, including Generics.
Not only that, but Darwazah also set out a bullish approach to deals and M&A, suggesting the firm was ready...




